Allergy & Immunology

Formoterol fumarate inhalation powder for asthma and COPD approved in Germany

Published in Medical Letter on the CDC and FDA, July 24th, 2005

SkyePharma PLC (SKP) announced that the German pharmaceutical regulatory authority has approved Foradil Certihaler (formoterol fumarate inhalation powder) for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Foradil Certihaler was co-developed by SkyePharma PLC and Novartis Pharma AG and is a trademark of Novartis. Foradil Certihaler was submitted for regulatory review in Europe on a country-by-country basis beginning in December 2002 and has now been approved in Switzerland, Austria, Finland, Portugal and the Netherlands as well as in Germany. It has also been approved in 5 countries in Latin America. It was also submitted for regulatory review...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry